Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of Alzheimer's disease; and preclinical stage to treat Parkinson's disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.
http://www.priceseries.com/trade/AVXL-Anavex-Life-Sciences-Corp-stock-gains-41-percent-a-Trade-Record-by-priceSeries-2020020320200224.html
Related Posts :
AXSM Axsome Therapeutics, Inc. gains 20% Oct 25, 2021Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in develop… 
INOD Innodata Inc. gains 26% Oct 25, 2021Innodata Inc. operates as a global data engineering company in the United States, the Uni… 
SRLP Sprague Resources LP gains 15% Oct 25, 2021Sprague Resources LP engages in the purchase, storage, distribution, and sale of refined … 
BAP Credicorp Ltd. gains 15% Oct 26, 2021Credicorp Ltd., through its banking and non-banking subsidiaries, provides a range of fin… 
BMTC Bryn Mawr Bank Corp. gains 20% Oct 25, 2021Bryn Mawr Bank Corporation operates as a bank holding company for The Bryn Mawr Trust Com…
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments